APA (7th ed.) Citation

Fashoyin‐Aje, L., Donoghue, M., Chen, H., He, K., Veeraraghavan, J., Goldberg, K. B., . . . Pazdur, R. (2019). FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1. The oncologist (Dayton, Ohio), 24(1), 103-109. https://doi.org/10.1634/theoncologist.2018-0221

Chicago Style (17th ed.) Citation

Fashoyin‐Aje, Lola, Martha Donoghue, Huanyu Chen, Kun He, Janaki Veeraraghavan, Kirsten B. Goldberg, Patricia Keegan, Amy E. McKee, and Richard Pazdur. "FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1." The Oncologist (Dayton, Ohio) 24, no. 1 (2019): 103-109. https://doi.org/10.1634/theoncologist.2018-0221.

MLA (9th ed.) Citation

Fashoyin‐Aje, Lola, et al. "FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1." The Oncologist (Dayton, Ohio), vol. 24, no. 1, 2019, pp. 103-109, https://doi.org/10.1634/theoncologist.2018-0221.